
Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) – Equities research analysts at HC Wainwright increased their Q3 2027 earnings per share (EPS) estimates for shares of Roivant Sciences in a research note issued to investors on Tuesday, November 10th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of ($0.44) per share for the quarter, up from their prior estimate of ($0.47). HC Wainwright has a “Buy” rating and a $48.00 price objective on the stock. The consensus estimate for Roivant Sciences’ current full-year earnings is ($2.00) per share. HC Wainwright also issued estimates for Roivant Sciences’ Q4 2027 earnings at ($0.50) EPS, FY2027 earnings at ($1.69) EPS and FY2028 earnings at ($2.09) EPS.
A number of other research analysts have also weighed in on ROIV. Jefferies Financial Group raised their target price on Roivant Sciences from $42.00 to $52.00 and gave the company a “buy” rating in a report on Tuesday, September 8th. UBS Group set a $55.00 price target on Roivant Sciences in a report on Wednesday, September 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Roivant Sciences in a research report on Tuesday. TD Cowen reissued a “buy” rating on shares of Roivant Sciences in a research report on Wednesday, October 21st. Finally, Bank of America restated a “neutral” rating on shares of Roivant Sciences in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $46.82.
Get Our Latest Research Report on Roivant Sciences
Roivant Sciences Stock Performance
Shares of ROIV opened at $38.96 on Friday. The firm has a market capitalization of $28.23 billion, a P/E ratio of -61.84 and a beta of 1.23. Roivant Sciences has a 52 week low of $19.96 and a 52 week high of $42.50. The stock has a 50 day moving average price of $37.22 and a two-hundred day moving average price of $32.59.
Insider Activity
In other Roivant Sciences news, Director Daniel Gold sold 602,021 shares of Roivant Sciences stock in a transaction that occurred on Tuesday, November 17th. The shares were sold at an average price of $38.24, for a total transaction of $23,021,283.04. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Melissa B. Epperly sold 17,750 shares of Roivant Sciences stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $36.10, for a total transaction of $640,775.00. Following the transaction, the director directly owned 14,954 shares in the company, valued at approximately $539,839.40. This represents a 54.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 2,892,393 shares of company stock valued at $110,548,437. 8.80% of the stock is currently owned by company insiders.
Institutional Trading of Roivant Sciences
Institutional investors and hedge funds have recently modified their holdings of the business. Assenagon Asset Management S.A. lifted its holdings in Roivant Sciences by 18.2% during the second quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company’s stock worth $295,965,000 after acquiring an additional 1,286,464 shares during the period. Perceptive Advisors LLC boosted its position in Roivant Sciences by 3.8% in the first quarter. Perceptive Advisors LLC now owns 8,285,461 shares of the company’s stock worth $229,507,000 after purchasing an additional 300,000 shares during the last quarter. Pictet Asset Management Holding SA boosted its position in Roivant Sciences by 20.3% in the third quarter. Pictet Asset Management Holding SA now owns 4,173,123 shares of the company’s stock worth $152,597,000 after purchasing an additional 704,783 shares during the last quarter. Wellington Management Group LLP grew its stake in Roivant Sciences by 179.0% in the 2nd quarter. Wellington Management Group LLP now owns 2,687,870 shares of the company’s stock valued at $95,124,000 after purchasing an additional 1,724,588 shares during the period. Finally, Bank of America Corp DE grew its stake in Roivant Sciences by 8.0% in the 1st quarter. Bank of America Corp DE now owns 3,163,821 shares of the company’s stock valued at $87,638,000 after purchasing an additional 235,493 shares during the period. 64.76% of the stock is owned by hedge funds and other institutional investors.
About Roivant Sciences
Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.
See Also
- Five stocks we like better than Roivant Sciences
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
